...
首页> 外文期刊>Vaccine >LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb.
【24h】

LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb.

机译:LT-IIc是II型不耐热肠毒素家族的新成员,显示出与LT-IIa或LT-IIb诱导的免疫调节特性不同的有效免疫调节特性。

获取原文
获取原文并翻译 | 示例

摘要

A plethora of human pathogens invade and/or colonize mucosal surfaces. Elaboration of strong, protective immune responses against those pathogens by mucosal vaccination, however, is hampered by endogenous regulatory systems in the mucosae that dampen responses to foreign antigens (Ags). To overcome those natural barriers, mucosal adjuvants must be employed. Using a mouse mucosal immunization model and AgI/II, a weak immunogen from Streptococcus mutans, LT-IIc, a new member of the type II subgroup of the heat-labile enterotoxin family, was shown to have potent mucosal adjuvant properties. In comparison to mice intranasally immunized only with AgI/II, co-administration of AgI/II with LT-IIc enhanced production of Ag-specific IgA antibodies in the saliva and vaginal fluids and Ag-specific IgA and IgG in the serum. Secretion of IL-2, IL-6, IL-17, IFN- gamma , and TNF- alpha was enhanced in cultures of AgI/II-stimulated splenic cells isolated from mice that had received LT-IIc as a mucosal adjuvant. In contrast, secretion of IL-10 was suppressed in those cells. This pattern of cytokine secretion suggested that LT-IIc stimulates both Th1 and Th2 immune responses. In contrast to LT-IIa and LT-IIb, the original members of the type II subgroup that also are mucosal adjuvants, LT-IIc dramatically enhanced secretion of IL-1 alpha and IL-1 beta in peritoneal macrophages that had been co-cultured with LPS. Furthermore, the B pentameric subunit of LT-IIc augmented uptake of Ag by bone marrow-derived dendritic cells to levels that exceeded those attained by use of LPS or by the B pentamers of LT-IIa or LT-IIb. These data confirmed that LT-IIc is a strong mucosal adjuvant with immunomodulatory properties that are distinguishable from those of LT-IIa and LT-IIb and which has immunomodulatory properties that may be exploitable in vaccine development.
机译:大量人类病原体侵入和/或定殖在粘膜表面。然而,通过粘膜接种来形成针对那些病原体的强的,保护性的免疫应答,受到粘膜中抑制对外源抗原(Ags)的应答的内源性调节系统的阻碍。为了克服这些天然障碍,必须使用粘膜佐剂。使用小鼠粘膜免疫模型和AgI / II,变异链球菌的弱免疫原LT-IIc是热不稳定肠毒素家族II型亚群的新成员,被证明具有很强的免疫力。粘膜佐剂特性。与仅用AgI / II鼻内免疫的小鼠相比,AgI / II与LT-IIc共同给药可增强唾液和阴道液中Ag特异性IgA抗体的产生以及血清中Ag特异性IgA和IgG的产生。在从接受了LT-IIc作为粘膜佐剂的小鼠分离的AgI / II刺激的脾细胞培养物中,IL-2,IL-6,IL-17,IFN-γ和TNF-α的分泌得以增强。相反,在那些细胞中IL-10的分泌被抑制。这种细胞因子分泌的模式表明LT-IIc刺激Th1和Th2免疫反应。与LT-IIa和LT-IIb(也属于粘膜佐剂的II型亚组的原始成员)相反,LT-IIc大大增强了共培养的腹膜巨噬细胞中IL-1α和IL-1β的分泌使用LPS。此外,LT-IIc的B五聚体亚基增加了骨髓来源的树突状细胞对Ag的摄取,使其水平超过了使用LPS或LT-IIa或LT-IIb的B五聚体所达到的水平。这些数据证实了LT-IIc是具有与LT-IIa和LT-IIb的免疫调节特性不同的免疫调节特性的强粘膜佐剂,并且具有可以在疫苗开发中利用的免疫调节特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号